The ATP binding cassette (ABC) transporter protein Yor1p was identified on the basis of its ability to elevate oligomycin resistance when it was overproduced from a high-copy-number plasmid. Analysis of the predicted amino acid sequence of Yor1p indicated that this protein was a new member of a subfamily of ABC transporter proteins defined by the multidrug resistance protein (MRP). In this work, Yor1p is demonstrated to localize to the Saccharomyces cerevisiae plasma membrane by both indirect immunofluorescence and biochemical fractionation studies. Several mutations were generated in the amino-terminal nucleotide binding domain (NBD1) of Yor1p to test if the high degree of sequence conservation in this region of the protein was important for function. Deletion of a phenylalanine residue at Yor1p position 670 led to a mutant protein that appeared to be retained in the endoplasmic reticulum (ER) and that was unstable. As shown by others, deletion of the analogous residue from a second mammalian MRP family member, the cystic fibrosis transmembrane conductance regulator (CFTR), also led to retention of this normally plasma membrane-localized protein in the ER. Changes in the spacing between or the sequences flanking functional motifs of Yor1p NBD1 led to defective trafficking or decreased activity of the mutant proteins. Analyses of the degradation of wild-type and ⌬F670 Yor1p indicated that the half-life of ⌬F670 Yor1p was dramatically shortened. While the vacuole was the primary site for turnover of wild-type Yor1p, degradation of ⌬F670 Yor1p was found to be more complex with both proteasomal and vacuolar contributions.
Multiple-drug resistance has often been linked with increased expression of ATP-binding cassette (ABC) transporter proteins that act as multispecific drug efflux pumps (see reference 15 for a review). The first known ABC transporter protein mediating multidrug resistance was human MDR1. MDR1 is localized to the plasma membranes of cells and is overexpressed in an array of multidrug-resistant cell lines and tumors (reviewed in reference 57). Biochemical experiments indicate that MDR1 transports compounds that typically have not been modified by the cell (reviewed in reference 16).
More recently, a second ABC transporter has been found in multidrug-resistant lung tumor cells (8) . This ABC transporter protein, designated multidrug resistance protein (MRP), has several properties that make it distinct from MDR1. First, MRP transports modified substrates, such as glutathione and glucuronide conjugates (28, 36, 39, 45) . Second, while both MDR1 and MRP possess a repeating structure of a set of transmembrane domains followed by the characteristic ABC transporter nucleotide binding domain, MRP has an additional set of transmembrane domains at its amino terminus (2) . Finally, nucleotide binding domain 1 (NBD1) of MRP exhibits a characteristic spacing of functional motifs and high sequence similarity that serves to define a group of ABC transporter proteins referred to as the MRP family (8) .
Like all known ABC transporters, NBD1 of the MRP family contains a Walker A, LSGGQ, and Walker B element (26, 64) . The identical spacing of these elements in NBD1 of the MRP family serves to define this class of ABC transporter proteins (8) . A second conserved feature in the MRP family NBD1 region is the presence of a phenylalanine residue between the Walker A and LSGGQ motifs. This phenylalanine was shown to be precisely deleted from an MRP family member, the human cystic fibrosis (CF) transmembrane conductance regulator (CFTR), in 60% of patients with CF (62) . Wild-type CFTR must arrive at the plasma membrane to function normally, and deletion of this phenylalanine residue (⌬F508) causes the resulting mutant protein to be retained in the endoplasmic reticulum (ER) (7) , where it is degraded by the proteasome (29, 65) .
Saccharomyces cerevisiae has also been found to contain a group of ABC transporter proteins showing the characteristic structural features indicative of the MRP family. Ycf1p was the first member of the S. cerevisiae MRP family and was identified by its important role in cadmium tolerance (60) . A second member of the S. cerevisiae MRP family was cloned as a key determinant of oligomycin resistance (9, 33) . This ABC transporter protein was designated Yor1p (stands for yeast oligomycin resistance protein).
In this work, we localize Yor1p to the plasma membrane in cells. Analyses of wild-type and mutant forms of Yor1p suggest that the trafficking and turnover of this yeast protein have remarkable similarity to those of human CFTR. As seen for the major disease-associated allele of CFTR (⌬F508), degradation of an analogous form of Yor1p involves multiple proteolytic systems.
spin at 4°C. Protein concentration was measured in 1% sodium dodecyl sulfate (SDS) by the method of Lowry et al. (40) . Protein extracts were solubilized in an equal volume of sample buffer (40 mM Tris-HCl [pH 6.8], 8 M urea, 15% SDS, 0.1 mM EDTA, 1% ␤-mercaptoethanol, 0.01% bromophenol blue) and heated to 37°C for 20 min. Equal amounts of protein were subjected to electrophoresis on SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and probed with the antibody indicated below. For immunodetection of Yor1p, the C-terminal antibody was used for all Western blot and indirect immunofluorescence analyses and the N-terminal antibody was employed for all immunoprecipitation experiments. Immunoreactive material was detected with a donkey anti-rabbit immunoglobulin conjugated to horseradish peroxidase (Amersham) and by chemiluminescence (Pierce).
Immunoprecipitation, pulse-labeling, and chase. Labeling and immunoprecipitations were performed essentially as described in reference 11 with the following modifications. Cells were grown overnight in complete synthetic medium to an OD 600 of 0.3 to 0.5. Cells lacking a temperature-sensitive allele were then harvested, resuspended in fresh prewarmed medium without methionine to an OD 600 of 2, and incubated for 10 min with gentle shaking. Cells were metabolically labeled by adding 15 Ci of Express protein labeling mix (New England Nuclear) per OD 600 unit of cells and shaking at 30°C for 10 min. A 100ϫ chase solution containing 100 mM ammonium sulfate, 0.3% L-cysteine, and 0.4% L-methionine was added to the culture following labeling, and aliquots (5 ϫ 10 7 cells) were removed. The sec12-3 cells were grown at 23°C and shifted to 37°C for 10 min to impose the sec12-3 block or left at 23°C to permit continued Sec12-3p function. Following the temperature shift, cells were labeled at either the permissive or the restrictive temperature for 10 min and chased as described above. Time point aliquots were transferred to chilled tubes, and sodium azide was added to a final concentration of 10 mM. Cells were washed once with 10 mM sodium azide and resuspended in 200 l of lysis buffer (15 mM Tris [pH 7.6], 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1ϫ Boehringer Mannheim complete protease inhibitors). Glass beads were added, and cells were lysed by vigorously vortexing them three times for 1 min each time, with 1-min cooling intervals. SDS was then added to 1%, and two more 1-min vortexing rounds were performed. The resulting protein extracts were diluted with 5 volumes of immunoprecipitation (IP) buffer (15 mM Tris [pH 7.6], 150 mM NaCl, 1% Triton X-100, 2 mM sodium azide) and cleared by centrifugation. Polyclonal anti-Yor1p (1:100 dilution of the anti-N-terminal antibody) was added to the cleared lysate and incubated at 4°C in an end-over-end rotator for 1 h. Following this incubation, preswollen protein A-Sepharose beads (Sigma) were added and incubated end-over-end overnight at 4°C. Immune complexes bound to protein A-Sepharose beads were washed three times with IP buffer containing 0.1% SDS and two times with detergent-free wash buffer (10 mM Tris [pH 7.6], 50 mM NaCl, 2 mM sodium azide), resuspended in 40 l of sample buffer, and heated to 37°C for 20 min. Twenty microliters of each sample was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) (7.5% acrylamide), fixed in 7.5% acetic acid, soaked in 1 M sodium salicylate (pH 6.0) for 30 min, dried, and subjected to autoradiography or quantitated by phosphorimaging (Packard Cyclone).
Cell fractionation and sucrose gradient density centrifugation. Cellular membranes were resolved by sucrose gradient density centrifugation essentially as described in references 35 and 53. Cells (100 ml) were grown to an OD 600 of 0.3 to 0.5, sodium azide and potassium fluoride were added to 10 mM, and then the cells were briefly chilled on ice and harvested. Cells were then washed once in 10 mM sodium azide-10 mM potassium fluoride-5 mM Tris (pH 7.6) and resuspended in 0.5 ml of STE10 plus protease inhibitors (10% sucrose, 10 mM Tris [pH 7.6], 10 mM EDTA, 1ϫ Boehringer Mannheim complete protease inhibitors). Glass beads were added, and the suspension was vortexed for 2 min. An additional 1 ml of STE10 plus protease inhibitors was then added and vortexed, and the supernatant was transferred to a new tube. This lysate was clarified by centrifugation for 3 min at 300 ϫ g. Three hundred microliters of this cleared supernatant was then loaded onto a linear sucrose gradient prepared by sequentially layering STE solutions containing 10, 20, 35, or 60% sucrose to form a 5-ml step gradient. When sucrose gradients were centrifuged in the presence of Mg 2ϩ , we used the same protocol except that the sucrose solutions were prepared in TM buffer (10 mM Tris [pH 7.6], 1 mM MgCl 2 ). Each gradient was then tipped to a horizontal position and allowed to diffuse for 5 h. The gradients were then returned to an upright position, loaded with extract, and subjected to 14 h of centrifugation in a SW55.1 rotor (Beckman) at 50,000 rpm and 4°C. Fractions (380 l) were collected from the top of the gradient, and proteins were precipitated with trichloroacetic acid. Protein samples were neutralized with the addition of 10 l of 1 M Tris base and resuspended by heating them in 50 l of sample buffer at 37°C for 30 min. The protein composition of each fraction was then analyzed by SDS-PAGE followed by Western blotting with appropriate antibodies. Indirect immunofluorescence. Immunofluorescence experiments were performed essentially as described previously (51, 67) . Cells (50 ml) were grown to an OD 600 of approximately 0.5 in either yeast extract-peptone-dextrose or selective medium, at which point 5.8 ml of 37% formaldehyde was added directly to the culture. The culture was then shaken at 30°C for an additional 30 min. Cells were then harvested by centrifugation, resuspended in paraformaldehyde fixative (51) lacking MgCl 2 , and gently shaken overnight at room temperature. Fixed cells were washed four times in 1 ml of sorbitol buffer (1.2 M sorbitol, 50 mM sodium phosphate [pH 6.5]) with 1% ␤-mercaptoethanol and resuspended in 1 ml of sorbitol buffer minus ␤-mercaptoethanol. Spheroplasting was performed by adding 20 l of a 1-mg/ml solution of oxylyticase (Enzogenetics) and shaking the suspension for 20 min at 30°C. Spheroplasted cells were then washed three times in sorbitol buffer and permeabilized by adding SDS to 0.05% and incubating the cells at 30°C for 5 min. Permeabilized cells were then washed three times with sorbitol buffer, adsorbed to polyethylenimine-coated slides, and exposed to antibodies. Yor1p was visualized by decoration with an affinity-purified anti-Yor1p (C-terminal) antibody and an anti-rabbit fluorescein isothiocyanate-conjugated goat antibody (Organon Teknika). Confocal microscopy was performed by standard techniques at the University of Iowa Electron Microscopy Center with a Bio-Rad confocal imaging system fitted to a conventional microscope with a 100ϫ lens objective. Images were filtered by Kalman averaging and merged. Images were obtained and processed identically.
RESULTS
Wild-type Yor1p localizes to the plasma membrane by indirect immunofluorescence. We have previously described the isolation of the YOR1 gene on the basis of its important role in mediating oligomycin resistance (33) . From the striking sequence similarity between Yor1p and other ABC transporter proteins of the MRP subfamily, we speculated that Yor1p might mediate oligomycin resistance through action as a multidrug transporter protein. To gain insight into the possible mechanism of Yor1p function, the subcellular location of the protein was determined. Indirect immunofluorescence experiments were carried out with affinity-purified antibodies that recognize the carboxy terminus of Yor1p (33) . Immunofluorescence was first performed on strain SEY6210 (YOR1) and its isogenic yor1-1::hisG derivative DKY7. As can be seen in Fig. 1 , the wild-type strain showed a highly punctate staining pattern around the periphery of the cell similar to that seen for other plasma membrane-targeted ABC transporter proteins (11, 49) . No specific immunofluorescence was visible in the yor1-1::hisG mutant cells, confirming that the staining pattern in wild-type cells was specific for Yor1p. Overproduction of Yor1p from a high-copy-number plasmid carrying the wildtype gene led to a dramatic increase in the level of plasma membrane staining by the anti-Yor1p antibody. This result is consistent with the increased presence of Yor1p at the plasma membrane, which correlates with the increased oligomycin re-FIG. 1. Yor1p localization by indirect immunofluorescence. Isogenic strains with various levels of the YOR1 gene were prepared for indirect immunofluorescence essentially as described previously (67) . Strains carried the yor1-1::hisG allele (left panels), had a single copy of YOR1 (middle panels), or were transformed with the wild-type YOR1 gene carried on a 2 m plasmid (right panels). Cells were labeled with affinity-purified rabbit anti-Yor1p C-terminal antibody, followed by incubation with fluorescein isothiocyanate-conjugated goat anti-rabbit antibody.
sistance seen in these cells (33) . We interpret these data as providing evidence for the plasma membrane being the functional site for Yor1p activity.
To confirm the plasma membrane localization of Yor1p indicated by the indirect immunofluorescence experiments, a wild-type cell lysate was fractionated on a sucrose gradient. The distributions of Yor1p and several marker proteins of known subcellular locations were compared by Western blot analysis with appropriate antisera (Fig. 2) . Yor1p was enriched in the highest-density fractions of the sucrose gradient in a manner similar to that of the plasma membrane marker Pma1p (55) . The distribution of the ER membrane protein Sec61p (59) was distinctly different from that of Yor1p and was most highly enriched in the lower-density fractions of the gradient. Markers for the Golgi membrane, Vps10p (also called Pep1p) (43) , and the vacuolar membrane, Vph1p (42), were also enriched in the lower-density regions of the gradient. This sucrose gradient analysis provides strong support for the belief that Yor1p is localized to the plasma membrane.
Mutagenesis of the first nucleotide binding domain of Yor1p. ABC transporters are defined by their characteristic nucleotide binding domains. Like other nucleotide binding proteins, ABC transporters contain Walker A and Walker B motifs (64) . However, the sequence similarity of ABC transporters extends over the entire nucleotide binding domain and is further defined by the presence of a short peptide sequence (LSGGQ) that lies between the Walker A and B elements (26) . While the spacing between these three functional motifs is similar in all ABC transporter proteins, different families of these related proteins have been identified based on variations in the lengths of sequences separating the Walker A, Walker B, and LSGGQ motifs. One of these groups has been referred to as the MRP family since the sequence of this ABC transporter protein originally served to define this strictly conserved spacing (8) . Sequence analysis of Yor1p indicated that this protein was also a member of the MRP family of ABC transporters, and an alignment showing the conserved spacing and sequences of several members of this group is shown in Fig. 3 .
To explore the functional significance of the conserved spacing and primary sequence shared by Yor1p and the MRP family, several different site-directed mutations were produced in the NBD1 region of the YOR1 gene. The phenylalanine residue at position 670 in Yor1p corresponds to a phenylalanine that is conserved in all the MRP family members. Removal of this phenylalanine residue from CFTR was previously shown to eliminate normal plasma membrane targeting of this protein and to cause the resulting ⌬F508 mutant of CFTR to be retained in the ER (7). The potential functional role of the corresponding phenylalanine residue in Yor1p was evaluated by constructing a ⌬F670 allele of YOR1.
Three other mutant versions of Yor1p were generated. While NBD1 of Yor1p clearly shows the striking sequence identity of the MRP family, computer analysis of this region in Yor1p indicates that a single amino acid gap must be introduced into the Yor1p sequence in order to maintain the alignment with the sequences of other family members (33) . To examine the functional relevance of this one amino acid gap, an alanine was inserted into the predicted position of the gap. Additionally, experiments with both CFTR and Ycf1p have suggested that changing the basic residue immediately following the LSGGQ motif in these two proteins to methionine or VOL. 19, 1999 TRAFFICKING OF Yor1p 3001
on December 21, 2017 by guest http://mcb.asm.org/ glutamine produces a derivative with increased function (47, 61, 67) . The lysine at Yor1p position 715 was changed to either methionine or glutamine to determine if these alterations could increase the function of Yor1p. Functions and expression of mutant Yor1p derivatives. Each mutant form of Yor1p was analyzed for its relative ability to complement the oligomycin-hypersensitive phenotype of a strain lacking a functional YOR1 structural gene. Mutant YOR1 genes were introduced on low-copy-number plasmids into a strain carrying the yor1-1::hisG allele and analyzed by spot test assay on plates containing a gradient of oligomycin (Fig. 4) . The ⌬F670 YOR1 allele was also introduced on a high-copy-number plasmid to determine if residual function could be detected when the mutant protein was overproduced.
None of the mutant Yor1p derivatives were able to confer oligomycin resistance to a level approaching that of the wildtype protein. The ⌬F670 Yor1p form was the most highly defective and exhibited oligomycin tolerance that was indistinguishable from that of yor1-1::hisG cells carrying the vector alone, irrespective of the presence of this mutant allele on a low-or high-copy-number plasmid. The insertion of alanine at position 652 (insA652) severely reduced the function of the resulting mutant Yor1p. Finally, the two replacements of the basic residue downstream of the LSGGQ motif (K715M and K715Q) produced forms of Yor1p that were highly defective in the ability to confer oligomycin resistance.
To ensure that the observed changes in oligomycin tolerance were due to alterations in protein function rather than in amount, steady-state levels of each mutant protein were compared to those of the wild-type by Western blot analysis (Fig.  5 ). All the mutant Yor1p forms were produced at levels comparable to those of the wild-type protein with the exception of ⌬F670 Yor1p. This mutant derivative was consistently detected at a reduced steady-state level relative to that of the wild-type protein, suggesting that this lesion reduced the stability of Yor1p. Even when ⌬F670 Yor1p was overproduced from a 2m plasmid, the functional defect of this mutant protein was not suppressed. Since the levels of the ⌬F670 Yor1p form produced from the 2m plasmid are even higher than those of the wild-type protein, the functional defect caused by the ⌬F670 lesion cannot be solely due to the decreased levels of the steady-state protein.
Localization of mutant Yor1p derivatives. The Western blot data above confirmed that the observed defects seen in these mutant forms of Yor1p were not due to an effect on the levels of synthesis of these proteins. The localization of the mutant transporter proteins was next assessed by biochemical fractionation on sucrose gradients. The positions of the various forms of Yor1p and marker proteins of known subcellular distribution were determined by Western blotting (Fig. 6) .
The first mutant Yor1p form examined was the ⌬F670 derivative. ⌬F670 Yor1p was easily detectable in the sucrose gradient fractions and showed a distinct pattern of enrichment relative to that of the wild-type protein. ⌬F670 Yor1p was found to enrich in the center of the sucrose gradient, while Yor1p was concentrated towards the most dense regions of the gradient. When the same gradient fractions were probed with the anti-Pma1p antiserum, the characteristic enrichment of this integral plasma membrane protein was seen in the most dense fractions of the gradient. However, unlike the wild-type protein, ⌬F670 Yor1p was seen to enrich in the fractions of the gradients that contained the ER marker Sec61p and the Golgi or endosomal marker Vps10p. These data are consistent with the hypothesis that ⌬F670 Yor1p fails to normally exit the ER during its biosynthesis and that it fails to reach the plasma membrane. This aberrant location of ⌬F670 Yor1p is likely to at least contribute to the functional defect of this protein.
The K715Q and insA652 Yor1p forms were also analyzed by Western blotting of sucrose gradient fractions. Both of these mutant proteins exhibited a fractionation pattern intermediate between those of the wild-type and ⌬F670 forms of Yor1p. The fractionation behavior of the insA652 form of Yor1p was closer to that of ⌬F670 Yor1p, as the majority of the insA652 derivative was present in the center of the gradient. However, unlike ⌬F670 Yor1p, detectable levels of the insA652 protein were found associated with the most dense sucrose gradient fractions. K715Q Yor1p was clearly present in the densest fractions of the gradient but was also seen to modestly accumulate in the center of the gradient. Since the trafficking defect of K715Q Yor1p is less pronounced than that of the insA652 form, we ascribe the large reduction in function seen in cells expressing K715Q Yor1p to a reduction in the activity of this protein. These data suggest that both the K715Q and the insA652 Yor1p have defects of varying severities in their ability to move out of the ER. However, defective trafficking is most likely to explain the defect in the insA652 allele while a decrease in activity of the K715Q protein seems more consistent with the behavior of this mutant Yor1p derivative.
The stability of ⌬F670 Yor1p is reduced relative to that of the wild-type protein. The reduced steady-state levels of ⌬F670 Yor1p suggested that this mutant derivative might be less stable than the corresponding wild-type protein. To directly test this possibility, pulse-chase analysis was carried out on strains expressing either the wild-type or ⌬F670 form of Yor1p. Cells were labeled with [ 35 S]methionine and then incubated in a large excess of unlabeled amino acids. Aliquots were withdrawn at various times, and Yor1p was recovered by immunoprecipitation. Immunoprecipitated material was resolved by SDS-PAGE, followed by autoradiography or phosphorimaging (Fig. 7) .
The wild-type protein was degraded with a half-life of approximately 42 min, while the half-life of ⌬F670 Yor1p was only 15 min, demonstrating the markedly increased rate of turnover of this mutant form of Yor1p. This result indicates that ⌬F670 Yor1p has two defects relative to the wild-type protein: altered subcellular localization and decreased stability. The two forms of immunoprecipitable Yor1p seen in Fig. 7 (top panels) are believed to be due to cleavage by vacuolar proteases during sample processing since the lower form of Yor1p does not appear in pep4 cells (see below) and does not display a precursor-product relationship over time.
In analyses of other plasma membrane-localized ABC transporter proteins, Ste6p and Pdr5p, it was found that these proteins were delivered to the vacuole for degradation after their residence in the plasma membrane (3, 11, 35) . To examine the involvement of vacuolar proteases in the turnover of Yor1p and mutant derivatives, a pep4 strain was employed. Loss of the PEP4 gene strongly depresses maturation of vacuolar proteases and stabilizes proteins that are normally degraded in the vacuole (1, 31) . The levels of degradation of wild-type and ⌬F670 Yor1p were compared in isogenic wild-type and pep4 cells by pulse-chase analysis. FIG. 6 . Subcellular fractionation of Yor1p NBD1 mutants. Cells lacking a chromosomal YOR1 locus (DKY7) were transformed with low-copy-number plasmids bearing the genes that express the indicated forms of Yor1p. Lysates were prepared and centrifuged through sucrose gradients as described in the legend to Fig. 2 . Aliquots of each sucrose gradient were then subjected to Western blotting with the affinity-purified anti-Yor1p antibody (Yor1p) or the rabbit anti-Pma1p (Pma1p), rabbit anti-Vps10p (Vps10p), or rabbit anti-Sec61p (Sec61p) antiserum as listed on the right-hand side of each panel. The orientation of the sucrose gradient fractions is indicated as in Fig. 2 .
Loss of the PEP4 gene led to a large increase in the stability of wild-type Yor1p (Fig. 7) . The half-life of Yor1p increased from 42 min in a PEP4 background to 284 min in the absence of Pep4p. This result clearly implicated normal vacuolar protease levels in the turnover of Yor1p. The behavior of ⌬F670 Yor1p in response to the presence of the PEP4 gene was also examined. The half-life of ⌬F670 Yor1p was increased from 15 to 58 min when the PEP4 gene was deleted. While the turnover of both the wild-type protein and ⌬F670 Yor1p was reduced in the pep4 background, the half-lives of these two ABC transporters were still very different. Even in the absence of vacuolar proteases, ⌬F670 Yor1p exhibited a half-life that was only 20% that of the wild-type protein in the same genetic background. However, the half-life of ⌬F670 Yor1p was longer in a pep4 mutant strain than in the isogenic PEP4 cells. This result was unexpected, as we hypothesized that ⌬F670 Yor1p was trapped in the ER and expected it to be turned over by the ER degradation system, as was shown for other defective proteins retained in this organelle (13, 18, 24, 68) . Typically, loss of vacuolar proteases does not affect turnover of proteins that are targets for degradation in the ER (13, 19) .
To further assess if ⌬F670 Yor1p was both retained and degraded in the ER, we carried out two additional experiments. First, additional sucrose gradient analyses were performed under different conditions to ascertain that ⌬F670 Yor1p was localized in the ER. Second, a cell containing a temperature-sensitive allele of the SEC12 gene was used to demonstrate that ⌬F670 Yor1p was degraded even if ER-toGolgi apparatus transport was arrested.
Roberg et al. (53) . Extracts were prepared from wild-type and pep4 cells expressing either wild-type or ⌬F670 Yor1p. This analysis was performed on pep4 cells to ensure that if a fraction of ⌬F670 Yor1p arrived at the vacuole, it would not be degraded by vacuolar proteases. These extracts were then resolved on sucrose gradients either in the presence or in the absence of Mg 2ϩ as described previously (53) . Aliquots of each fraction were collected and analyzed by Western blotting with antibodies directed against Yor1p, Sec61p, and Vph1p.
In cells containing an intact PEP4 gene (Fig. 8) , the fractionation profiles of both wild-type and ⌬F670 Yor1p, Sec61p, and Vph1p were the same as previously discussed (Fig. 2 and  6 ). However, when Mg 2ϩ was included in the gradient, the peaks of immunoreactivity of both ⌬F670 Yor1p and Sec61p were dramatically shifted to the denser fractions of the gradient. The new peaks of these two proteins were now present in fractions previously found to be enriched in the plasma membrane protein Pma1p. The Western blot profiles of wild-type Yor1p and Vph1p were slightly compressed towards the fractions of higher density, since both of these integral membrane proteins are likely to have some amount of ER precursor that will be shifted to the high-density fractions upon inclusion of Mg 2ϩ . This same fractionation protocol was carried out on a pep4 mutant strain expressing either wild-type or ⌬F670 Yor1p. Loss of the PEP4 gene did not affect the fractionation profile of either form of Yor1p (Fig. 8) . This finding provides strong evidence against the notion that ⌬F670 Yor1p reaches the vacuole, where it can be acted on by vacuolar proteases. Since inactivation of the vacuolar proteases failed to allow ⌬F670 Yor1p to be detected in vacuole-enriched fractions, we argue that ⌬F670 Yor1p is unlikely to be degraded in this organelle. This observation is consistent with the idea that ⌬F670 Yor1p is degraded in the ER by the proteasome.
To examine whether ⌬F670 Yor1p is a target of the ER degradation system, we prepared a strain carrying a sec12-3 temperature-sensitive mutation that expressed either the wildtype or the ⌬F670 form of Yor1p. Sec12p is required to form vesicles from the ER membrane during ER-to-Golgi apparatus transport (46) . The sec12-3 strain expressing these two forms of Yor1p was then analyzed by a pulse-chase immunoprecipitation experiment at the permissive and restrictive temperatures to assess the stability of wild-type and ⌬F670 Yor1p (Fig. 9) .
The pulse-chase immunoprecipitation demonstrated that the stability of wild-type Yor1p increased upon imposition of the sec12-3 block. This finding is consistent with the idea that wild-type Yor1p must leave the ER to be degraded in a Pep4p-dependent manner. In opposition to the stabilization seen for wild-type Yor1p after the temperature shift of the sec12-3 strain, ⌬F670 Yor1p was degraded with similar kinetics at both the permissive and restrictive temperatures. This finding indicates that inactivation of the SEC12 gene product failed to stabilize ⌬F670 Yor1p and supports the hypothesis that this mutant protein is degraded at the level of the ER. However, final confirmation that ⌬F670 Yor1p is trapped in the ER awaits detection of this mutant protein by microscopic techniques which have not yet been successful (data not shown). To directly explore the contribution of the ER degradation system to the turnover of ⌬F670 Yor1p, we used mutant backgrounds that were defective in this proteolytic machinery.
Proteasome-mediated turnover of ⌬F670 Yor1p. The simplest explanation for the observed stabilization of ⌬F670 FIG. 7 . Vacuolar proteases influence the turnover of both wild-type and ⌬F670 Yor1p. Isogenic yor1-1::hisG strains that either contained (top panels) or lacked (bottom panels) the PEP4 locus were transformed with low-copy-number plasmids bearing the gene that expresses the wild-type or ⌬F670 form of Yor1p. Selected transformants were then analyzed by pulse-chase analysis followed by immunoprecipitation with the anti-Yor1p antiserum or an anti-CPY polyclonal antibody (from R. Piper). Levels of immunoprecipitated proteins were quantitated by phosphorimaging. The time scale for the pulse-chase in the PEP4 background was in minutes, while that for the pulse-chase with the pep4 strain was in hours. The position of Yor1p and the positions of the various forms of CPY (58) are denoted by arrows.
Yor1p by a pep4 mutation is a direct role for vacuolar proteases in the turnover of this protein. However, it is also possible that the pep4 defect acts indirectly to deplete a component required for normal proteasome-mediated turnover of proteins trapped in the ER. A candidate for such an indirect action is depletion of ubiquitin, as the vacuole is an important site for degradation of ubiquitinated proteins that arrive here after endocytosis from the plasma membrane (reviewed in reference 23). The absence of degradation has the potential to affect ubiquitin metabolism in a fashion that may depress degradation of ⌬F670 Yor1p.
To determine if changes in ubiquitin levels could reverse the apparent stabilization of ⌬F670 Yor1p that was observed in the pep4 mutant background, we transiently increased ubiquitin levels in pep4 cells and examined the effect on the stability of ⌬F670 Yor1p. This was accomplished through use of a CUP1-ubiquitin fusion gene that produces high levels of ubiquitin when cells are exposed to copper (12) . Strains lacking pep4 and expressing either wild-type or ⌬F670 Yor1p from low-copynumber plasmids were transformed with a plasmid carrying a CUP1-ubiquitin fusion gene. Transformants were grown in the presence or absence of copper and evaluated for stability of Yor1p by pulse-chase analysis.
Induction of the CUP1-ubiquitin fusion gene by copper caused a dramatic destabilization of ⌬F670 Yor1p in the pep4 mutant strain (Fig. 8) . The half-lives of ⌬F670 Yor1p were 64 and 22 min when the protein was evaluated in the absence and presence of copper, respectively. Turnover of wild-type Yor1p was not affected by addition of copper. Treatment of cells lacking the CUP1-ubiquitin fusion gene with copper failed to
2ϩ -dependent fractionation of ⌬F670 Yor1p in PEP4 or pep4 cells. Lysates were prepared from PEP4 (A) or pep4 (B) cells expressing either wild-type or ⌬F670 Yor1p. These lysates were subjected to sucrose gradient centrifugation in the presence or absence of Mg 2ϩ as described previously (53) . Aliquots of the gradient were then analyzed by Western blotting (see Materials and Methods) for the presence of either form of Yor1p and for Sec61p or Vph1p.
VOL. 19, 1999 TRAFFICKING OF Yor1p 3005 influence the turnover of either form of Yor1p (data not shown). This experiment supported the idea that ⌬F670 but not wild-type Yor1p was subject to ubiquitin-dependent protein turnover. Ubiquitin-dependent degradation involves conjugation of a ubiquitin moiety to a target protein (reviewed in reference 63). This reaction requires the participation of ubiquitin-conjugating enzymes termed Ubc proteins in S. cerevisiae (25) . The ubiquitin peptide is transferred to the target protein, which in turn is subjected to degradation by the proteasome (25) . We tested the involvement of a Ubc enzyme (Ubc7p) and the proteasome in the turnover of ⌬F670 Yor1p by using mutant strains defective in these loci. A ubc7 mutant was selected, as other studies have shown that loss of this gene influences the turnover of other proteins that are degraded in the ER (5, 24) . A yor1-1::hisG ubc7 strain was constructed and transformed with low-copy-number plasmids expressing either wild-type or ⌬F670 Yor1p. The stability of Yor1p was examined by pulse-chase analysis (Fig. 10) .
The turnover of wild-type Yor1p was not affected by loss of UBC7. The wild-type Yor1p half-life was 42 min in the UBC7 background and 50 min in the ubc7 strain. However, the turnover of ⌬F670 Yor1p was depressed upon loss of Ubc7p, changing from 15 min in a UBC7 strain to 37 min in a ubc7 cell. These data are consistent with a role for Ubc7p in the ubiquitin-dependent turnover of ⌬F670 Yor1p.
Along with that of Ubc7p, we examined the contribution of the proteasome to the degradation of ⌬F670 Yor1p. A yor1-1::hisG pre1-1 pre2-2 strain was constructed, and the levels of stability of wild-type and ⌬F670 Yor1p were assessed by pulse-chase analysis as described above (Fig. 11) . Low-copynumber plasmids bearing PRE1 and PRE2 were also introduced into this background in order to restore proteasome function (21, 22, 68) .
Loss of proteasome activity increased the half-life of ⌬F670 Yor1p to a value indistinguishable from that of the wild-type protein (52 versus 53 min). Restoring the PRE1 and PRE2 genes decreased the stability of ⌬F670 Yor1p to 18 min but FIG. 9 . Effect of loss of Sec12p function on turnover of wild-type and ⌬F670 Yor1p. A strain containing the temperature-sensitive sec12-3 allele and lacking the YOR1 gene was constructed by one-step gene disruption of the YOR1 locus to produce EAE18. Low-copy-number plasmids bearing the gene that expresses either the wild-type or ⌬F670 form of Yor1p were then introduced into this gene background. Turnover of these two forms of Yor1p was then assessed by pulsechase immunoprecipitation analysis at the permissive (23°C) and restrictive (37°C) temperatures. The numbers refer to times in minutes after chase addition. had no significant effect on the degradation of wild-type Yor1p. These data are consistent with the turnover of ⌬F670 Yor1p occurring through the ER degradation pathway in a fashion similar to that described for 3-hydroxy-3-methylglutaryl-coenzyme A reductase (18) and carboxypeptidase Y mutants (24) .
DISCUSSION
Polarized epithelial cells express both MRP and a closely related protein designated the multispecific organic anion transporter (c-MOAT) (48) . In these polarized cells, MRP and c-MOAT are localized to the basolateral and apical membranes, respectively (reviewed in reference 34). Analyses of the complement of ABC transporters found in the S. cerevisiae genome have shown that a family of MRP-related transporters, including Yor1p and Ycf1p, is present in this organism (10, 44) . This work has identified Yor1p as a plasma membranetargeted transporter. Previous studies have defined Ycf1p as a component of the vacuolar membrane (37, 67) . Thus, S. cerevisiae expresses a family of MRP-related ABC transporters and these transporters are destined for delivery to different membrane locations in the cell. These results illustrate the conserved physiology of the MRP family of proteins between animal cells and S. cerevisiae, supporting the notion that analysis of this fungal MRP family will provide valuable insight into the function of the cognate mammalian proteins.
One of the most intensively studied integral membrane proteins with respect to its intracellular trafficking is the human CFTR (52), associated with the disease CF. Most CFTR alleles associated with CF, including the most common CF-associated allele, ⌬F508, have the effect of causing CFTR to be trapped in the ER (62, 66) . We probed NBD1 of Yor1p by mutagenesis to determine if this segment of the protein was similarly important in the biogenesis of this closely related yeast ABC transporter protein.
The ⌬F670 allele of Yor1p produced a transporter protein that exhibited trafficking behavior striking in its similarity to that of the ⌬F508 CFTR. These experiments suggest that ⌬F670 Yor1p is trapped in the ER in a fashion analogous to that of ⌬F508 CFTR (7). At least two explanations can be proposed to explain the consequences of the loss of this NBD1 phenylalanine codon: (i) important primary sequence information is deleted and (ii) spatial relationships are disturbed in the deletion mutants. The finding that the spacing of the functional motifs in Yor1p NBD1 is shorter by 1 amino acid than in the other members of the MRP family (33) suggested that the spacing within this region might be flexible. To investigate this possibility, we inserted an alanine residue at the gap in Yor1p NBD1 to convert the spacing of this protein to that seen for the other MRP members. This mutant exhibited trafficking behavior that was reminiscent of that of the wild-type CFTR. CFTR matures very slowly in the ER, with approximately 75% of the protein never reaching the plasma membrane (41) . Analysis of the insA652 Yor1p derivative suggests that this mutant protein is much slower to leave the ER than wild-type Yor1p but that a small amount is capable of reaching the plasma membrane. This is seen both in the immunoreactive insA652 Yor1p being in the densest fractions of the sucrose gradient and in the weak but reproducible oligomycin resistance conferred by this mutant factor. In contrast, ⌬F670 Yor1p could not be detected in the dense sucrose gradient fractions and failed to complement the oligomycin hypersensitivity of a yor1 strain.
One of the most surprising features of ⌬F670 Yor1p was the stabilization of this protein that occurred upon loss of the PEP4 gene. Vacuolar proteases have not been observed to affect the stability of other integral membrane proteins that are degraded in the ER (14, 19, 38, 50) . The rescue of this apparent stabilization by overexpression of ubiquitin has at least two possible explanations. First, it is possible that ⌬F670 Yor1p turnover is especially sensitive to levels of ubiquitin that may be slightly reduced in pep4 mutant strains. Elevation of ubiquitin levels may replenish whatever ubiquitin pool has been depleted. Second, vacuolar protease function may be required to produce an activity important in ⌬F670 Yor1p turnover at the ER. This possibility has precedent, as degradation of ⌬F508 CFTR has been found to involve several distinct proteolytic systems (29) . Overproduction of ubiquitin might enhance proteasome function and allow accelerated turnover of ⌬F670 Yor1p by this proteolytic system, although under normal conditions, the proteasome would be one of several contributors to the degradation of ⌬F670 Yor1p. The recent demonstration that proteins can leave the yeast vacuole (6) is consistent with the notion that the vacuole may provide protein maturation as well as degradation function. Experiments are under way to further investigate the role of pep4 on ⌬F670 Yor1p turnover.
A final issue concerning the degradation of ⌬F670 Yor1p is the precise localization of this factor. While our data support the belief that this mutant protein is retained in the ER, we cannot eliminate the possibility that ⌬F670 Yor1p is found in   FIG. 11 . A functional proteasome is required for rapid degradation of ⌬F670 Yor1p. A yor1-1::hisG mutant cell lacking normal proteasome function (pre1-1 pre2-2) was transformed with low-copy-number plasmids bearing the gene for either the wild-type or ⌬F670 form of Yor1p. Low-copy-number plasmids carrying PRE1 and PRE2 (pPRE1/pPRE2) or the vector plasmids alone (pRS313/pRS315) were introduced into these transformants to examine the consequence of varying the activity of the proteasome on turnover of these two forms of Yor1p. Appropriate transformants were analyzed for stability of wild-type or ⌬F670 Yor1p by pulse-chase analysis as described above. The calculated half-lives (T 1/2 ; in minutes) are on the right. (30) . It will be important to determine if ⌬F670 Yor1p is also found in these aggresome structures. Substitutions in the basic residue immediately following the LSGGQ motif in the MRP family members CFTR and Ycf1p have been found to have dramatic effects on the function of the resulting mutant proteins. A Ste6p-CFTR chimera containing CFTR NBD1, which failed to function in the presence of the ⌬F508 form of NBD1, regained activity when either Q or M replaced the arginine downstream of the NBD1 LSGGQ (61) . A Ycf1p derivative containing a mutation analogous to ⌬F508 (Ycf1p ⌬F713), did not respond to Q or M replacement of the lysine following its NBD1 LSGGQ (67) . Interestingly, an otherwise wild-type Ycf1p containing the K758Q or K758M lesion exhibited markedly increased function (67) . These data from analyses of other MRP family members led us to expect that analogous replacements in Yor1p would elevate its biological function. However, both Yor1p K715Q and K715M are defective in function relative to that of the wild-type protein and K715Q Yor1p exhibits a modest defect in normal plasma membrane fractionation as evidenced by an elevated level of Yor1p immunoreactivity in the region of the sucrose gradient corresponding to the ER. Taken together, these data are consistent with the basic residue following the NBD1 LSGGQ motif being a key determinant in the folding and transport of the MRP family of ABC transporters. In certain instances (CFTR, Ycf1p), alteration of this residue can make the protein fold or be transported more rapidly, while in other instances (Yor1p), alterations of this position depress the ability to fold and/or transport.
Irrespective of the exact explanation behind the observed defects elicited by the NBD1 mutations that we have generated in Yor1p, alterations in this domain of Yor1p have dramatic effects on the function of the resulting mutant transporter protein. This sensitivity can be contrasted with the resistance of the a-factor transporter Ste6p to changes in function caused by alterations in the primary sequence of its NBD1 region (4) . Two different single amino acid deletions in Ste6p NBD1 were found to have no detectable effect on the function of the resulting mutant protein. This comparison serves to illustrate the importance of the conserved spacing and high sequence conservation in the MRP family of proteins compared to that in other ABC transporter proteins of similar overall structure.
With Yor1p and CFTR, alterations in the NBD1 region often lead to a defect in transport from the ER. In the case of the ⌬F alleles of CFTR or Yor1p, the resulting trafficking defect also results in enhanced proteolysis of the mutant protein. Both of the ⌬F variants become substrates for ubiquitindependent proteolysis catalyzed by the proteasome. The finding of the similarity in molecular phenotype exhibited by ⌬F508 CFTR and ⌬F670 Yor1p provides the opportunity for genetic analysis of the mechanisms underlying the cell biology of the intracellular handling of this important class of ABC transporters.
